sábado, 31 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 18, 2026

Liberty Global outlines Ziggo Group spin-off and targets $1.5B corporate cash by 2026 amid major UK/Netherlands transactions

View original at seekingalpha.com
Liberty Global outlines Ziggo Group spin-off and targets $1.5B corporate cash by 2026 amid major UK/Netherlands transactions Earnings Call Insights: Liberty Global (LBTYA) Q4 2025 MANAGEMENT VIEW * Michael Fries, Vice Chairman, President, CEO & Chairman of the Board, highlighted two major new transactions: the acquisit…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is no strategy or plan to build fiber in the Netherlands and we don't believe it's necessary from commercial or capital perspective

    80% confidence
  • $500 million synergy target is annual, not cumulative

    80% confidence
  • Liberty Telecom's four national FMC champions generated $22 billion revenue and $8 billion EBITDA on aggregate basis

    80% confidence
  • VMO2 adjusted free cash flow guidance for 2026 is around GBP 200 million supporting cash distributions to shareholders of same amount

    80% confidence
  • 30% of VMO2 guidance impact attributed to B2B restatement including Daisy, 70% to cautious view on fixed consumer market

    80% confidence
  • 8 million Nexfibre homes will be achieved relatively quickly by end of 2027, with first priority to grow own customer base on 20 million home network and provide wholesale opportunity

    80% confidence
  • VMO2 revenue declined 5.9% on reported basis impacted by lower Nexfibre construction revenues and sustained competitive pressure

    80% confidence
  • Liberty Global anticipates ending 2026 with $1.5 billion in cash pro forma for announced transactions and expected asset sales

    80% confidence
  • All 3 large operating companies hit their guidance targets last year

    80% confidence
  • Liberty Corporate expected to have around $50 million negative adjusted EBITDA in 2026

    80% confidence
  • Net corporate spend reduced by 75% over last 12 months

    80% confidence
  • There are no minimum penetration or migration commitments in the Netomnia Nexfibre transaction

    80% confidence
  • We are serious about delivering value to shareholders and our structure today is fit for purpose

    80% confidence
  • Ziggo spin-off storyline comparable to Sunrise with deleveraging from free cash flow, EBITDA growth and asset sales expected to be visible by 2027

    80% confidence
  • Operating companies in UK, Netherlands and Belgium delivered on full year guidance metrics despite challenging market conditions

    80% confidence
  • Liberty Global announced 2 significant transactions and this is exactly what we said we would do on our call last year and the year before

    80% confidence
  • Liberty Global fully refinanced all 2028 maturities following successful term loan refinancings, senior secured note issuances and private taps

    80% confidence
  • Still have plenty of time for Telenet refinancing and can reprice debt and extend maturity as steps unfold

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,525 documentos-fonte arquivados
Consulte estes dados → isubstrate.com